18 patents
Utility
Muco-adhesive, Controlled Release Formulations of Levodopa And/or Esters of Levodopa and Uses Thereof
28 Sep 23
The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising levodopa.
Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
Filed: 6 Apr 23
Utility
Stabilized Formulations of 4-AMINO-3-SUBSTITUTED Butanoic Acid Derivatives
13 Jul 23
Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use.
David PENAKE, Sharon HAMM, Leonard O’MAHONY, John DEVANE, Wolfgang MOHR, Manuel WEINHEIMER
Filed: 16 Mar 23
Utility
Compositions and Methods of Administering Baclofen
29 Jun 23
Injectable baclofen formulations and methods that are bioequivalent in terms of plasma baclofen exposure to oral dosage forms but with reduced exposure ratios of baclofen to the M1 metabolite.
Leonard O'MAHONY, John DEVANE, Sharon HAMM, David PENAKE
Filed: 9 Nov 22
Utility
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
23 May 23
Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use.
David Penake, Sharon Hamm, Leonard O'Mahony, John Devane, Wolfgang Mohr, Manuel Weinheimer
Filed: 28 May 20
Utility
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
11 Apr 23
The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.
Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
Filed: 10 Jul 21
Utility
Baclofen Formulations and Methods of Minimizing Patient Exposure to Metabolite Variations
6 Apr 23
Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.
Leonard O'MAHONY, Sharon HAMM, John DEVANE, David PENAKE
Filed: 11 Jul 22
Utility
Muco-adhesive, Controlled Release Formulations of Levodopa And/or Esters of Levodopa and Uses Thereof
23 Mar 23
The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.
Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
Filed: 4 Oct 22
Utility
Levodopa Dosing Regimen
23 Feb 23
The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication.
Richard D'Souza, Hester Visser, Suneel Gupta
Filed: 17 Oct 22
Utility
Compositions and methods of administering baclofen
13 Dec 22
Injectable baclofen formulations and methods that are bioequivalent in terms of plasma baclofen exposure to oral dosage forms but with reduced exposure ratios of baclofen to the M1 metabolite.
Leonard O'Mahony, John Devane, Sharon Hamm, David Penake
Filed: 12 Nov 21
Utility
Baclofen formulations and methods of minimizing patient exposure to metabolite variations
8 Nov 22
Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure to baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.
Leonard O'Mahony, Sharon Hamm, John Devane, David Penake
Filed: 29 Sep 21
Utility
Stabilized Formulations of 4-AMINO-3-SUBSTITUTED Butanoic Acid Derivatives
25 Aug 22
Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use.
David PENAKE, Sharon HAMM, Leonard O'MAHONY, John DEVANE, Wolfgang MOHR, Manuel WEINHEIMER
Filed: 28 May 20
Utility
Levodopa Dosing Regimen
30 Jun 22
The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease.
Richard D'Souza, Hester Visser, Suneel Gupta
Filed: 21 Dec 21
Utility
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
14 Jun 22
The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
Filed: 13 Jan 21
Utility
Immunosuppressive Dosage Forms and Methods of Use
3 Feb 22
The present disclosure relates to formulations, methods, kits, and dosage forms for oral pharmaceutical formulations comprising one or more immunosuppressive agents.
Padam Bansal, Hardik Patel, Amitkumar Patel, Suhaskumar Patel
Filed: 21 Oct 21
Utility
Muco-adhesive, Controlled Release Formulations of Levodopa And/or Esters of Levodopa and Uses Thereof
4 Nov 21
The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.
Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
Filed: 10 Jul 21
Utility
Muco-adhesive, Controlled Release Formulations of Levodopa And/or Esters of Levodopa and Uses Thereof
6 May 21
The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
Filed: 13 Jan 21
Utility
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
27 Apr 21
The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
Filed: 17 Sep 19
Utility
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
13 Apr 21
The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and a method of using the controlled release oral solid formulation to treat Parkinson's disease or primary parkinsonism.
Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
Filed: 1 May 20
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first